腹膜透析患者的抗肿瘤药物：系统评价。
Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review.
机构信息
Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
出版信息
Crit Rev Oncol Hematol. 2020 Jun;150:102947. doi: 10.1016/j.critrevonc.2020.102947. Epub 2020 Apr 4.
BACKGROUND
There is no clear consensus on the administration of anti-neoplastic agents to patients on peritoneal dialysis. Dose adjustments to prevent serious adverse events are still not established. Thus, the aim of this study was to systematically review current evidence on the use of systemic oncology therapies in peritoneal dialysis.
METHODS
A systematic review was conducted using PubMed, Scopus, and Cochrane. All relevant data was collected, including clinical and pharmacokinetic parameters, with comparison to subjects with normal renal function.
RESULTS
Sixteen studies were included. All were case reports. Eighteen types of anti-cancer drugs were reviewed. Multiple adverse events and altered pharmacokinetics were reported.
CONCLUSION
Data concerning the use of anti-neoplastic drugs in patients on peritoneal dialysis are still sparse. The elimination of anti-cancer agents seems often altered in such patients, resulting in serious adverse events. Based on the available evidence, we suggest the need for dose adjustment of each drug.
背景
目前对于腹膜透析患者使用抗肿瘤药物尚无明确共识。为了预防严重不良事件而进行的剂量调整仍未建立。因此，本研究旨在系统地回顾目前关于在腹膜透析中使用全身肿瘤治疗的证据。
方法
使用 PubMed、Scopus 和 Cochrane 进行了系统回顾。收集了所有相关数据，包括临床和药代动力学参数，并与肾功能正常的患者进行了比较。
结果
共纳入 16 项研究，均为病例报告。共回顾了 18 种抗肿瘤药物。报道了多种不良事件和改变的药代动力学。
结论
关于腹膜透析患者使用抗肿瘤药物的数据仍然很少。这些患者中抗癌药物的消除似乎经常改变，导致严重的不良事件。基于现有证据，我们建议需要调整每种药物的剂量。
Zotero 插件